Companies Dominating the Esketamine Nasal Spray Market
- Eli Lilly & Company
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Company
- Novartis International AG
- Bausch Health Companies Inc.
- Validus Pharmaceuticals LLC
- Pfizer Inc.
- AbbVie Inc.
- Merck KGaA
- Endo International Plc
- MedKoo Biosciences, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of esketamine nasal spray is estimated at USD 27.11 billion.
The esketamine nasal spray market size was over USD 25.63 billion in 2024 and is anticipated to cross USD 60.28 billion by 2037, growing at more than 6.8% CAGR during the forecast period i.e., between 2025-2037. Increasing cases of depression in people worldwide will fuel the market growth.
North America industry is estimated to hold largest revenue share of 38% by 2037, owing to increasing cases of depression in the region.
The major players in the market are Eli Lilly & Company, Bristol Myers Squibb Company, Novartis International AG, Bausch Health Companies Inc., Validus Pharmaceuticals LLC, Pfizer Inc., AbbVie Inc., Merck KGaA, Endo International Plc, MedKoo Biosciences, Inc., Janssen Global Services, LLC, Otsuka Pharmaceutical Co., Ltd., Biogen Inc., Sage Therapeutics, Inc.
